Haematology is a dual laboratory and clinical specialty, and a Portfolio Pathway application must evidence both: laboratory morphology, coagulation and transfusion, and the clinical management of haemato-oncology, haemostasis and general haematology. FRCPath in Haematology, or a clearly comparable qualification, is effectively required, since it is mandatory for CCT. It is a Group 2 specialty, so not a dual GIM application, and pathology specialties generally accept evidence from the last ten years. Most candidates take two to four years.
The haematology route in brief
Haematology reaches the Specialist Register by the same two routes as every specialty: a Certificate of Completion of Training (CCT) at the end of UK training, or the Portfolio Pathway for doctors who have not completed a UK approved programme but can demonstrate equivalent knowledge, skills and experience. If you are new to the route, start with the complete guide to the Portfolio Pathway; this article assumes that grounding and focuses on what is specific to haematology.
What makes haematology distinctive is that it straddles two worlds. A UK consultant haematologist is responsible for the haematology laboratory, advising on and authorising results, blood films, coagulation and transfusion, and at the same time manages patients clinically, often the sickest in the hospital, through haemato-oncology, bone marrow transplant, haemostasis and general haematology. The curriculum is built around that combined role, and an application that is strong on one side and thin on the other is incomplete by definition.
The spine of your application is the General Medical Council (GMC) Specialty Specific Guidance (SSG) for Haematology, read alongside the haematology curriculum, which is run jointly by the Federation of the Royal Colleges of Physicians and the Royal College of Pathologists (RCPath). Read both before gathering anything, plus the resources from the British Society for Haematology. We explain how to read an SSG in general in the SSG guide.
The laboratory and clinical dual role
The single most important thing to understand about evidencing haematology is the balance between laboratory and clinical work. Both are core capabilities, and the assessors expect to see both demonstrated independently and to a consultant standard. This is the strand most overseas applicants find hardest, because in many health systems the laboratory and clinical roles are separated into different specialties.
Laboratory haematology
- Blood film and bone marrow morphology
- Coagulation interpretation and authorisation
- Transfusion medicine and compatibility
- Laboratory management and governance
- Advising clinicians on result interpretation
Clinical haematology
- Haemato-oncology: leukaemia, lymphoma, myeloma
- Bone marrow and stem cell transplant
- Haemostasis, thrombosis and anticoagulation
- General and inpatient haematology
- Acute haematological emergencies and end of life care
If your background is predominantly clinical, plan deliberately to evidence the laboratory side: morphology reporting, coagulation and transfusion authorisation, and laboratory governance. If your background is predominantly laboratory, plan to evidence the clinical management of patients. The dedicated guide on the laboratory and clinical balance goes deeper on how to build evidence on whichever side is currently thinner.
FRCPath: the mandatory examination
For haematology the qualification requirement is firmer than for most specialties. Possession of FRCPath in Haematology by examination is mandatory for the award of a CCT, so for the Portfolio Pathway you need FRCPath, or clear evidence of a comparable qualification and standard. This is the first thing to confirm, because without it, or a genuinely comparable qualification, the application cannot succeed however strong the rest of the evidence.
The FRCPath examination is structured around four roughly equal areas: blood transfusion, general haematology including laboratory management, haematological oncology, and haemostasis and thrombosis. That structure is a useful map of the breadth your evidence must also cover. If you do not hold FRCPath, settle whether your qualifications are accepted as comparable before investing years in the portfolio.
The curriculum capabilities
The haematology curriculum is built on Capabilities in Practice (CiPs): high-level descriptions of what a day-one consultant can do, spanning both the laboratory and clinical roles. Knowing the specialty capabilities helps, because they are the framework your portfolio will be mapped against.
These specialty capabilities sit alongside the generic professional capabilities shared across medicine. The underlying logic of CiPs, and how to map evidence to them, sits in the Capabilities in Practice guide, within the four GMC domains.
Not a GIM application, and the ten-year evidence window
Two structural points distinguish haematology from the medical specialties covered elsewhere in this library. First, it is a Group 2 specialty, entered after internal medicine stage 1 training, so it is not a dual application with General Internal Medicine. You must demonstrate medical knowledge to the level of completion of internal medicine stage 1, but you do not evidence an ongoing general medical take. The dual nature of haematology is internal, between laboratory and clinic.
Second, and usefully, the currency-of-evidence rules differ. Pathology specialties including haematology generally accept evidence from the last ten years, a longer window than the five-year expectation common in many clinical specialties, although a small amount of older evidence can be considered where it completes the picture of breadth. The bulk should still be recent and give current assurance, but the longer window can help an experienced haematologist evidence the full range of the specialty.
The ten-year window means a strong case or a rare presentation from several years ago can still count toward breadth, provided your recent practice carries the application. Confirm the exact rule in your SSG, and use the longer window to evidence the parts of the curriculum your current post sees less often, such as a particular transplant or transfusion scenario.
A note for internationally trained applicants. The combined laboratory-and-clinical model is one of the harder things to evidence from overseas, because many health systems split haematology into a laboratory discipline and a separate clinical one. If your overseas practice covered only one side, you will need to build the other from inside a UK post, and you will also need FRCPath or a clearly comparable qualification. For most internationally trained haematologists the realistic route is therefore a UK post that offers the full role first, then the portfolio. Be honest about which side is currently thinner and plan deliberately to fill it.
Laboratory and procedural evidence
The laboratory side has its own evidence types that clinical applicants sometimes overlook. Morphology, coagulation, transfusion and laboratory governance all need to be demonstrated, not just asserted, and there are recognised ways to do so.
Bone marrow aspirate and trephine biopsy is the main procedural skill, and it should be logged and assessed like any other procedure. But the laboratory evidence is mostly cognitive: it is about demonstrating that you interpret, authorise and advise to a consultant standard, and that you contribute to the governance and accreditation that keeps a laboratory safe. Make that work visible rather than leaving it implied in your job title.
One strand that ties the two halves of the specialty together is the haematologist's role as a round-the-clock advisory service to the rest of the hospital. Acute leukaemia and tumour lysis, major haemorrhage and massive transfusion, anticoagulation reversal, thrombotic thrombocytopenic purpura and neutropenic sepsis are managed jointly by the laboratory and the clinical team, and the consultant haematologist is the person other specialties phone. Evidence of that advisory and on-call role, the decisions you led and the urgent advice you gave, demonstrates exactly the integrated laboratory-and-clinical judgement the curriculum is built around. It is some of the most distinctive evidence available to a haematologist, and it is easy to leave uncaptured because it happens in conversations rather than clinics.
What evidence you need
The laboratory and clinical strands sit within a complete application that maps across the whole curriculum using the same evidence types as every specialty. The table below is the working inventory.
The cross-specialty evidence types each repay being built deliberately. We cover the workhorses in depth: multi-source feedback, workplace-based assessments, audit, and structured reports and referees. A transfusion audit is a particularly efficient piece of evidence, because it touches the laboratory role, patient safety and governance at once.
Subspecialty breadth
Haematology is broad, and the FRCPath structure is a good guide to the breadth assessors expect. A portfolio strong in haemato-oncology but thin in haemostasis, or strong in clinical work but thin in transfusion, looks unbalanced against a curriculum built around the whole specialty. Think across these areas and make sure each is genuinely represented.
Haemato-oncology
The high-acuity clinical core.
- Leukaemia, lymphoma and myeloma
- Bone marrow and stem cell transplant
- Systemic anti-cancer therapy governance
- Neutropenic sepsis and emergencies
Haemostasis and thrombosis
The coagulation strand.
- Bleeding disorders and haemophilia
- Thrombosis and anticoagulation
- Major haemorrhage management
- Coagulation laboratory interpretation
Transfusion and general
The service backbone.
- Transfusion medicine and compatibility
- Haemoglobinopathies and anaemias
- General and laboratory haematology
- Laboratory management and accreditation
Haemato-oncology deserves a particular note because it carries a heavy governance load that is worth evidencing explicitly. Systemic anti-cancer therapy, complex transplant decisions, clinical trial participation and the haemato-oncology multidisciplinary team all involve protocols, registries and shared decision-making, and demonstrating that you operate safely within them shows consultant-level judgement rather than just clinical knowledge. Capturing your contribution to the multidisciplinary team, the cases you presented and the decisions you shaped, evidences the specialty capabilities and the teamwork domain at once, and it is exactly the kind of material that rounds out a portfolio.
If you have a defined special interest, whether that is transplant, haemostasis, haemoglobinopathies or transfusion medicine, lean into it as evidence of consultant-level depth, provided the general breadth is also there. The guide on special interest areas covers how to evidence one.
A realistic timeline
Most candidates take two to four years from starting evidence collection to Specialist Register entry, and haematology often needs the upper part of that range. You are evidencing two roles rather than one, and if you do not already hold FRCPath, the examination takes substantial preparation. The longer ten-year evidence window helps, but the breadth across laboratory and clinical work is genuinely demanding to assemble.
The processing time after submission is the same as for any specialty: the GMC's published guidance is six to twelve months to process before the Royal College evaluation, with the decision after that. Plan for roughly twelve to eighteen months from submission to outcome, on top of the evidence-building years. The full sequence is in the timeline guide, and what happens after you submit in the after-submission guide.
The biggest variable, as ever, is your post. A department giving you genuine laboratory responsibility, morphology and transfusion authorisation, bone marrow procedures, and clinical management across the subspecialties makes a complete application achievable. A post confined to one side of the specialty makes the other side very hard to evidence. That is worth weighing honestly when you plan, and sometimes worth acting on.
Why haematology applications stall
FRCPath not held or not comparable
The firmest eligibility gap. FRCPath in Haematology, or a clearly comparable qualification, is effectively required. Confirm this is satisfied before anything else.
One side of the specialty thin
Strong clinically but thin on laboratory and transfusion work, or the reverse. The curriculum is built around both roles, and assessors expect genuine evidence of each.
Transfusion under-evidenced
Transfusion medicine is a quarter of the specialty and a frequent gap. Evidence your transfusion advice, major haemorrhage role and governance explicitly.
Laboratory work left implicit
Authorising and advising every day but not capturing it. Make the morphology, coagulation and governance work visible and mapped to the laboratory capabilities.
Related guides
Haematology sits within the wider library of specialism overviews and the cross-cutting evidence guides. If you are still choosing or confirming your specialty, the guide on choosing your specialty helps. The full set of specialism overviews:
Build these alongside your application
The laboratory and clinical evidence is specialty-specific, but the rest of the portfolio draws on the same cross-cutting evidence types as every application. Build these in parallel.
Haematology is the clearest example of a specialty where one post rarely shows the whole picture. Genuine laboratory responsibility alongside clinical management, including transfusion and bone marrow work, is what makes a complete application possible. If your current post is confined to one side, a move to a department offering the full role is often the most effective thing you can do for your application, as well as your career.
Official sources used
| Publisher | Source |
|---|---|
| GMC | Specialty specific guidance: Haematology |
| JRCPTB / The Federation | Curriculum for Haematology Training |
| Royal College of Pathologists | FRCPath examinations in Haematology |
| RCPath | The Portfolio Pathway (formerly CESR) |
| British Society for Haematology | British Society for Haematology |
| GMC | Specialist registration through the Portfolio pathway |
| GMC | Good Medical Practice (2024) |
| RCPath | Training in haematology |
Frequently asked questions
Is haematology a laboratory or a clinical specialty?
Both, and that dual nature defines the application. UK haematologists run and advise the haematology laboratory, including morphology, coagulation and transfusion, and they manage patients clinically, from haemato-oncology and bone marrow transplant to haemostasis and general haematology. A Portfolio Pathway application must evidence competence across both the laboratory and the clinical sides. An applicant strong in clinical haematology but thin on laboratory and transfusion practice, or the reverse, has an incomplete application against a curriculum built around the combined role.
Do I need FRCPath in Haematology for the Portfolio Pathway?
Possession of FRCPath in Haematology by examination is mandatory for the award of a CCT, so for the Portfolio Pathway you need FRCPath or clear evidence of a comparable qualification and standard. This makes the qualification the first thing to confirm. The FRCPath examination covers blood transfusion, general haematology including laboratory management, haematological oncology, and haemostasis and thrombosis. If you do not hold FRCPath, check carefully against the Specialty Specific Guidance whether your qualifications are accepted before building the portfolio.
Is haematology assessed with General Internal Medicine?
No. Haematology is a Group 2 specialty, entered after internal medicine stage 1 training, so it is not a dual application with GIM in the way the Group 1 medical specialties are. You must demonstrate medical knowledge to the level of completion of internal medicine stage 1, but you do not evidence an ongoing general medical take. The dual nature of haematology is internal to the specialty, between the laboratory and clinical roles, rather than a separate GIM application.
What evidence does a haematology Portfolio Pathway application need?
Evidence mapped to the curriculum capabilities across both sides of the specialty: laboratory work including morphology, coagulation and transfusion, clinical management of haemato-oncology, haemostasis and general haematology, bone marrow procedures, the FRCPath, workplace-based assessments, multi-source feedback, audit and quality improvement, teaching and CPD, and structured reports. Acute haematological emergencies and end of life care are specific capabilities. Everything should be mapped to the relevant capability and clearly organised across the laboratory and clinical roles.
How far back can my haematology evidence go?
Pathology specialties including haematology generally accept evidence from the last ten years, a longer window than the five-year expectation common in many clinical specialties, although a small amount of older evidence can be considered where it completes the picture of breadth. The bulk of the evidence should still be recent and give current assurance. Confirm the exact position in your Specialty Specific Guidance, because the currency-of-evidence rules are defined there and matter to how you assemble the portfolio.
How long does the haematology Portfolio Pathway take?
Most candidates take two to four years from starting evidence collection to Specialist Register entry. Haematology often needs the upper part of that range because you are evidencing both the laboratory and clinical roles, and the FRCPath takes substantial preparation if you do not already hold it. Once submitted, the GMC takes six to twelve months to process before the Royal College evaluation, with the decision after that. Plan for roughly twelve to eighteen months of process time on top of the evidence-building years.